Skip to main content
Equibles

MARSHALL WACE, LLP

Position in TCRX — TScan Therapeutics, Inc.

CIK 1318757 LONDON, X0
Back to TCRX Full portfolio

Position in TCRX

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$673,616
+$433,897 QoQ
Shares Held
687,364
+189.6% QoQ
Ownership
1.01%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#14
of 60 holders
Holding Since
Dec 2023
10 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in TCRX Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

MARSHALL WACE, LLP holds $3,055,517,440 across 267 Biotechnology names. TCRX ranks #205 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 543,897 $270,169,956
2 INCY
Incyte Corp
 1,310,154 $148,519,056
3 RPRX
Royalty Pharma plc
 2,450,669 $137,409,009
4 SYRE
Spyre Therapeutics, Inc.
 991,693 $88,042,503
5 ALNY
Alnylam Pharmaceuticals, Inc.
 259,799 $78,207,292
6 TVTX
Travere Therapeutics, Inc.
 1,333,207 $75,739,488
7 MANE
Veradermics, Inc
 585,560 $71,988,746
8 DFTX
Definium Therapeutics, Inc.
 1,298,946 $61,102,419

All Filings in TCRX

Export CSV
10 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $673,616 687,364
2026-03-31 $239,719 237,346
2025-12-31 $339,240 339,240
2025-09-30 $84,866 46,630
2025-06-30 $77,832 53,678
2024-12-31 $133,665 43,969
2024-09-30 $822,496 165,160
2024-06-30 $1,798,798 307,487
2024-03-31 $1,517,897 191,171
2023-12-31 $644,511 110,551